Substance / Medication

Cyclophosphamide anhydrous

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

93 trials linked to this intervention

93
Total Trials
71
Recruiting
4
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia.
Grover Punita, Veilleux Olivier, Tian Lu et al. · Blood Adv · 2022
PMID: 34610109Meta-AnalysisFull text (PMC)
Chemotherapy Treatments for Burkitt Lymphoma: Systematic Review of Interventional Studies.
Della Rocca Ana M, Leonart Letícia P, Ferreira Vinicius L et al. · Clin Lymphoma Myeloma Leuk · 2021
PMID: 33947633Meta-Analysis
Malaria Infection and Risk for Endemic Burkitt Lymphoma: A Systematic Review and Meta-Analysis.
Kotepui Kwuntida Uthaisar, Kotepui Manas · Int J Environ Res Public Health · 2021
PMID: 34070881Meta-AnalysisFull text (PMC)
Cardiac complications and iron overload in beta thalassemia major patients-a systematic review and meta-analysis.
Koohi F, Kazemi T, Miri-Moghaddam E · Ann Hematol · 2019
PMID: 30729283Meta-Analysis
and cortical superficial siderosis in CAA: Meta-analysis and potential mechanisms.
Charidimou Andreas, Zonneveld Hazel I, Shams Sara et al. · Neurology · 2019
PMID: 31243071Meta-AnalysisFull text (PMC)
Cortical superficial siderosis and bleeding risk in cerebral amyloid angiopathy: A meta-analysis.
Charidimou Andreas, Boulouis Gregoire, Greenberg Steven M et al. · Neurology · 2019
PMID: 31732564Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Cyclophosphamide anhydrous (substance)
SNOMED CT
1268997008
UMLS CUI
C1880207

Clinical Data

This intervention maps to 25 entities in the Healos knowledge graph.

20
Conditions
3
Biomarkers
1
Specialists
0
Symptoms
93
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.